Hyalolex

**Hyalolex** is a proprietary oral cannabinoid-based combination supplement developed by India Globalization Capital for symptoms associated with Alzheimer's disease, including behavioral and psychological symptoms such as anxiety, aggression, and sleep disturbance. The company identified the original Alzheimer's-focused formulation as **IGC-507** and described it as an FDA-unapproved alternative oral combination therapy based on research licensed from the University of South Florida. Public company materials do not sufficiently disclose the complete, fixed active-ingredient composition of the original Hyalolex formulation to assign a definitive molecular mechanism. ([investor.igcpharma.com](https://investor.igcpharma.com/wp-content/uploads/2023/01/IGC-FilesPatentforHyalolexFormulation.pdf))

Brand names

HyalolexHyalolex Drops of Clarity